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Abstract
Background:  alpha-Methylacyl-CoA racemase (AMACR), an immunomarker for prostatic
adenocarcinoma, has been shown to be expressed in a variety of other neoplasms. This study aims
to evaluate immunohistochemical expression of the AMACR in neoplastic and nonneoplastic liver
lesions, and assess its value in the diagnosis of hepatocellular carcinoma (HCC).
Methods: Formalin-fixed paraffin-embedded tissue sections of 51 HCC (14 well, 22 moderately
and 15 poorly differentiated), 9 hepatocellular adenoma (HCA), 48 cirrhotic nodules (CN) and 16
normal liver tissues (NLT) were immunostained for AMACR.
Results: Expression of AMACR is significantly enhanced in HCC tissue compared with non-HCC
tissue. High expression of AMACR was found in 82% of HCC including 86% of well-differentiated
HCC. In contrast, only 11% of HCA, 13% of CN and 6% of NLT showed high expression for
AMACR. Clinicopathological evaluation showed a significant correlation between AMACR
expression and venous invasion and capsular invasion by HCC.
Conclusion: Our results suggest that AMACR staining may serve as a useful marker for the
differential diagnosis of well-differentiated HCC from HCA. Increased AMACR expression and its
association with tumor venous invasion suggest that AMACR may play a role in HCC development
and progression.
Background
Hepatocellular carcinoma (HCC) remains one of the
most common malignant neoplasms in the world, with
approximately 1 million new cases per year [1]. It is asso-
ciated with a variety of risk factors, including hepatitis
viruses B and C, environmental carcinogens, and genetic
disorders. The exact parthenogenesis of HCC remains
unclear [2]. The prognosis of HCC is generally poor; there-
fore, the accurate diagnosis is critical for successful treat-
ment and clinical outcomes [2,3].
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Despite many clinical aspects are taken into consideration
for the diagnosis of HCC, histological examination still
represents the gold standard. However, well differentiated
forms of HCC can be difficult to separate histomorpho-
logically from benign lesions such as hepatocellular ade-
noma (HCA), particularly in small biopsies [4,5]. Because
distinction between HCC and HCA is vitally important in
determining appropriate therapy and assessing prognosis,
many attempts have been made using immunohisto-
chemical stains to aid in such differential diagnosis [6].
However, the clinical application and reproducibility of
these immunostains still need to be further investigated
[7].
α-methylacyl-coenzyme A racemase (AMACR), a peroxy-
mal mitochondrial enzyme involved in the β-oxidation of
branched-chain fatty acids and fatty acid derivatives, is an
enzyme normally present in the peroxisome and mito-
chondria of renal tubular epithelial cells and hepatocytes.
AMACR was initially identified as a molecular marker for
prostate cancer on the basis of complementary DNA
(cDNA) microarray technology [8-10]. Various degree of
expression of AMACR has also been reported in other
types of neoplasms including HCC [11-13]. However, the
diagnostic value of AMACR staining in HCC, especially in
distinction between HCC and HCA, has not been
explored. Furthermore, clinicopathological relevance and
significance of AMACR expression in HCC remain
unknown. In the present study, we evaluated immunohis-
tochemical expression of the AMACR in neoplastic and
non-neoplastic liver lesions, and assessed the potential
diagnostic utility of AMACR in differential diagnosis of
HCC. The correlation of AMACC staining with clinical-
pathological factors of HCC was investigated.
Methods
Patients and Specimens
The study group was composed of patients submitted to
orthotopic liver transplantation or tumor resection at
Memorial Hermann Hospitals, affiliated hospital of Uni-
versity of Texas Health Science Center at Houston. Surgi-
cal pathology cases were evaluated, including 51 HCC (14
well-, 22 moderately and 15 poorly differentiated HCC)
with various pathological features, 9 cases of hepatocellu-
lar adenoma and 16 normal liver tissues. Cirrhotic nod-
ules (48 cases) are taken from non-cancerous tissue 1 cm
away from the tumor margin. Normal liver tissue excised
from traumatically injured liver (8 cases) and near hepa-
tocellular adenoma (8 cases) was reviewed. The HCC were
categorized into well (G1), moderately (G2), or poorly
(G3) differentiated types, corresponding to Edmondson's
grades I/II, III, or IV, respectively [14,15].
The age of patients with HCC ranged from 48 to 73 years,
with a mean age of 64.4 years. Of the 51 patients, 42 were
men and 9 were women. The etiology of chronic liver dis-
ease associated with HCC includes chronic hepatitis C
virus (HCV) infection (26 cases), chronic hepatitis B virus
(HBV) infection (3 cases), alcoholic cirrhosis (18 cases),
primary biliary cirrhosis (1 case), hemochromatosis (1
case) and cryptogenetic cirrhosis (2 cases). Patients with
HCA ranged in age from 26 to 48 years (mean, 33 years)
with a female-to-male ratio of 6:1. An association with
steroid hormone use was not recorded in these cases. Tis-
sues from the specimens were fixed in 10% buffered for-
malin, processed, and stained with hematoxylin and
eosin. All cases were reviewed to confirm the diagnosis
independently by 2 pathologists.
Immunohistochemical Staining
Immunohistochemical stains were performed on forma-
lin-fixed and paraffin-embedded 4-µm sections. The tis-
sue sections were deparaffined, and antigen retrieval
conditions included 0.1 M citrate buffer (pH 6.0) in an
800-W microwave oven for 15 minutes. The sections were
incubated in 3% hydrogen peroxidase to quench endog-
enous tissue peroxidase for 5 minutes. The tissue sections
were then incubated with a monoclonal antibody against
P504S at 1:80 dilution for 30 minutes at room tempera-
ture (Zeta Corp., Sierra Madre, CA). The slides were
stained in an automated immunostainer using a standard
avidin-biotin complex staining procedure. Immunohisto-
chemical reactions were developed with diaminobenzi-
dine as the chromogenic peroxidase substrate, and slides
were counterstained with hematoxylin. Prostatic carci-
noma served as the positive control. Negative controls
were performed for all cases and consisted of identically
prepared slides that were treated with antibody diluent
(Dako Corp.) in place of primary antibody, but otherwise
subjected to the same immunohistochemical staining
protocol.
Assessment of Immunohistochemical Staining
Positive AMACR expression was defined as cytoplasmic
staining with either a finely stippled or coarsely granular
pattern, which could be easily identified at low-power
magnification (<= 100×). Scant faint finely granular back-
ground staining, which could not be seen at low-power
magnification (<= 100×), was interpreted as negative
staining (background staining). Staining intensity was
graded as 0 (background staining), 1+ (weak), 2+ (mod-
erate), or 3+ (strong). Staining intensity was further
grouped into low staining intensity (grade as 0 or 1+) and
high staining intensity (grade as 2+ or 3+) for comparison.
Statistics
Mean values and standard deviations were calculated to
describe the data population. Statistical analyses were per-
formed using the Fisher exact test or two-tailed t test. A P
value of < 0.05 was considered to be significant.Journal of Experimental & Clinical Cancer Research 2008, 27:2 http://www.jeccr.com/content/27/1/2
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Results
Immunohistochemical expression of AMACR in HCC and 
non-HCC tissue
The distribution of AMACR protein expression in liver tis-
sue was examined by means of immunohistochemical
analysis of tissue samples. For statistical purpose, the
intensity of AMACR staining was scored using two scales:
"high expression" represented moderate (2+) or strong
(3+) staining while "low expression" indicated back-
ground (0) or weak (1+) staining.
Staining of the AMACR protein was detected in the cyto-
plasm of both HCC and non-HCC tissue. AMACR stain-
ing intensity was generally low (grade 0 or 1+) in NLT,
HA, and CN samples (Fig. 1A–C) while the vast majority
of HCC samples showed high AMACR expression(grade
2+ or 3+) (Fig. 1D). The results of AMACR immunohisto-
chemical staining for HCC, HA, CN and NLT were sum-
marized in Table 1. The high expression of AMACR was
present in 82% (42/51) of HCC. In contrast, only 11% (1/
9) of HCA, 13% (6/48) of CN and 6% (1/16) of NLT
showed high expression for AMACR. The difference in
AMACR high expression between HCC group and non-
HCC group was highly statistically significant (<0.001).
Among 51 cases of HCC, high expression of AMACR was
found in 86% (12/14) well-differentiated HCC, 82% (18/
22) moderately differentiated HCC and 80% (12/15)
poorly differentiated HCC. In both low grade (well- and
moderately differentiated) and high grade (poorly differ-
entiated) HCC, AMACR high expression was much more
frequent compared with HA, CN and NLT (p < 0.001). No
significant correlation was found between AMACR expres-
sion and HCC grade.
High expression of AMACR was significantly more fre-
quent in CN (13%) than in NLT (6%) (p < 0.01). No dif-
ference of AMACR expression was observed between CN
and HA, and between HA and NLT. AMACR showed no
staining in other types of cells of the liver, including bile
duct epithelium, endothelial cells, Kupffer cells, and stro-
mal cells.
Correlation between AMACR expression and 
clinicopathological parameters of HCC
Clinicopathological parameters were compared between
groups of high and low AMACR expression and the results
were listed in Table 2. High-intensity staining appeared to
correlate significantly with venous invasion (P  < 0.05)
and capsular invasion (P < 0.05). There was no significant
correlation between the expression of AMACR and other
clinicopathological variables (Table 2).
Discussion
AMACR has been established as a valuable diagnostic
marker for prostate carcinoma with high sensitivity and
specificity [8,9]. Despite many studies on AMACR expres-
sion in human cancer [11,16-18], few studies are available
describing the role of AMACR expression in HCC. Pub-
lished reports are limited to the assessments of the fre-
quency and distribution of its expression in HCC and
non-HCC tissues [11,13]. Studies by Guzman et al.
showed various degree and pattern of AMACR expression
in HCC and non-HCC tissues. In their study, the cases of
hepatocellular adenoma were not included and associa-
tion between AMACR expression and clinic pathological
parameters in HCC was not assessed [13].
In this study, the AMACR protein was detected in the cyto-
plasm of normal hepatocytes, and the staining were either
scant faint (background staining) or weakly positive.
These findings are consistent with results previously pub-
lished [13]. We demonstrated that AMACR expression is
significantly increased in the HCC compared with HCA,
Table 1: Expression of AMACR in HCC, HCA, CN and NLT
AMACR staining intensity* n (%)
Low expression High expression
0 1+ 2+ 3+ Total No. of Cases
HCC 0(0) 9(18) 16(31) 26(51) 51
WDHCC 0(0) 2 (14) 5 (36) 7 (50) 14
MDHCC 0(0) 4 (18) 6 (27) 12 (55) 22
PDHCC 0(0) 3 (20) 5 (33) 7 (47) 15
HCA 6(67) 2 (22) 1 (11) 0 (0) 9
CN 16 (33) 26 (54) 6 (13) 0 (0) 48
NLT 13(81) 2(13) 1(6) 0(0) 16
Note: WDHCC indicates well differentiated HCC;MDHCC: moderately differentiated HCC;PDHCC: poorly differentiated HCC;
HCA: Hepatocellular adenoma; CN: Cirrhotic nodules, NLT: normal liver tissue
*Staining intensity is graded as 0 (scant faint finely granular background staining), 1+ (weak), 2+ (moderate), or 3+ (strong).Journal of Experimental & Clinical Cancer Research 2008, 27:2 http://www.jeccr.com/content/27/1/2
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CN and NLT with respect to the intensity of immunostain-
ing. The high expression of AMACR was found in 82%
(42/51) of HCC, while only 11% (1/9) of HCA, 13% (6/
48) of CN and 6% (1/16) of NLT showed high expression
for AMACR. These findings suggest that AMACR may be
involved in the hepatocarcinogenesis. AMACR is impor-
tant in β-oxidation of branched-chain fatty acids. From
pathogenesis point of view, there is a possibility that a
molecular link exists between this metabolic fatty acid
enzyme and HCC. Experimental studies showed that over-
expression of acyl-CoA oxidase, regulated by AMACR, can
transform cells in vitro [19].
Separation of HCC from HCA, in particular the well-dif-
ferentiated variant, is a difficult challenge for pathologists.
Although helpful morphological criteria have been
worked out, there are still cases that cannot be reliably
resolved in routine practice [4]. Clinical parameters such
as sex, age, history of steroids, hepatitis or level of alpha-
fetoprotein may give indications, but not proof, in the dif-
ferential diagnosis. Since methods of treatment such as
embolization and surgery, are different for HCA and
HCC, an early correct diagnosis is of major importance.
Therefore, it is critical to develop relevant sensitive mark-
ers to assist in making an accurate diagnosis. We assessed
the potential diagnostic utility of AMACR in HCC. In our
study, high expression of AMACR was found in 82% of
well-differentiated HCC. In contrast, only 11% of HCA
showed high expression for AMACR. These results suggest
that AMACR may serve as a useful marker to facilitate
accurate diagnosis in specific settings, particularly in dis-
tinguishing well-differentiated HCC from HCA given that
Expression of AMACR in HCC and non-HCC tissue Figure 1
Expression of AMACR in HCC and non-HCC tissue. A, normal liver tissue (background staining, grade 0). B, hepatocel-
lular adenoma (background staining, grade 0). C, cirrhotic nodules (weakly positive, grade 1+). D, well-differentiated hepatocel-
lular carcinoma (strongly positive, grade 3+). (immunohistochemical staining; original magnification ×200)Journal of Experimental & Clinical Cancer Research 2008, 27:2 http://www.jeccr.com/content/27/1/2
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high AMACR expression is at much lower frequency in
HCA. Results may warrant further studies using large vol-
ume samples to evaluate the value of AMACR as a diag-
nostic marker in HCC.
Analysis of AMACR expression in relation to clinicopatho-
logical features showed that high AMACR in the HCC was
significantly associated with venous invasion. This data
suggests an important role of AMACR in tumor invasive-
ness and progression of HCC. Venous invasion is one of
the most important pathological features that lead to
postoperative tumor recurrence after resection of HCC
[20,21]. The exact mechanism of venous invasion in HCC
remains unclear, but active neovascularization of the
tumor is likely to play an important role. It is not clear
whether and to what extent AMACR is involved in angio-
genesis during HCC progression. Further studies are
needed to clarify the mechanisms.
Finally, the significance of our findings is that it may have
a potential target of therapy in HCC. High expression
which is present in a high percentage of HCC, but in only
small percentage or rarely in non-HCC tissue, suggests
that AMACR may be a target for cancer treatment by using
AMACR antibodies or enzyme inhibitors. In addition,
individuals with congenital absence of this enzyme have
no or only insignificant resultant clinical manifestations
[22,23], suggesting that no significant adverse effects will
occur in patients treated with anti-AMACR antibody or
enzyme inhibitors.
Conclusion
In summary, our study provides evidence that immuno-
histochemical detection of AMACR can be helpful in the
differential diagnosis between HCC and HCA, especially
in tumors of which histology alone is not sufficient for a
proper diagnosis. Overexpression of AMACR in HCC and
its significant correlation with venous invasion indicate
that AMACR may be involved in HCC development and
progression. The molecular mechanism(s) of AMACR in
HCC merits further investigation.
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